Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based biotech BeiGene (HKG: 6160, SHA: 688235, Nasdaq: BGNE) to carry out a Phase I clinical study assessing the safety and efficacy of Phanes’ PT199 combined with BeiGene’s tislelizumab in multiple advanced solid tumors.
PT199: Mechanism and Differentiation
PT199 is an anti-CD73 monoclonal antibody (mAb) with a differentiated mechanism of action, designed to fight against the adenosine-mediated immunosuppressive tumor microenvironment (TME) catalyzed by CD73. It can completely inhibit both soluble and membrane-bound CD73, setting it apart from other inhibitors that do not achieve complete CD73 inhibition.
Tislelizumab: Background and Approvals
Tislelizumab (BGB-A317), a humanized IgG4 mAb anti-PD-1, was first commercially launched in China in March 2020. It has been approved for nine indications in China, with five included on the National Reimbursement Drug List (NRDL).-Fineline Info & Tech
